VNDA Vanda Pharmaceuticals Inc.

8-K Current Report

Filed: February 23, 2026

Health Care

Pharmaceutical Preparations

Vanda Pharmaceuticals Inc. (VNDA) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• FDA approved Bysanti (milsaperidone) for two indications: acute bipolar I manic/mixed episodes and schizophrenia in adults
• Dual-indication approval significantly expands addressable market — schizophrenia and bipolar disorder are large, chronic-treatment psychiatric conditions

+1 more insights

Other Vanda Pharmaceuticals Inc. 8-K Filings

8-K Mar 10, 2026

Get deeper insights on Vanda Pharmaceuticals Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.